世界中医药
文章摘要
引用本文:李亚1,雷斯媛1,马艺钊1,赵贵香1,刘影1,张海龙1,2.中成药治疗慢性阻塞性肺疾病稳定期的网状Meta分析[J].世界中医药,2024,(10):.  
中成药治疗慢性阻塞性肺疾病稳定期的网状Meta分析
Network Meta-analysis of Chinese Patent Medicines for the Treatment of Stable Chronic Obstructive Pulmonary Disease
投稿时间:2023-04-18  
DOI:10.3969/j.issn.1673-7202.2024.10.010
中文关键词:  中成药  慢性阻塞性肺疾病  金水宝胶囊  百令胶囊  补肺活血胶囊  玉屏风颗粒  苏黄止咳胶囊  网状Meta分析
English Keywords:Chinese patent medicines  Chronic obstructive pulmonary disease  Jinshuibao Capsules  Bailing Capsules  Bufei Huoxue Capsules  Yupingfeng Granules  Suhuang Zhike Capsules  Network Meta-analysis
基金项目:国家中医药管理局中医药科学技术研究专项(GZY-KJS-2021-016);河南省特色骨干学科中医学学科建设项目(STG-ZYXKY-2020007);河南省中医药科学研究专项(2019JDZX2004)
作者单位
李亚1,雷斯媛1,马艺钊1,赵贵香1,刘影1,张海龙1,2 1 河南中医药大学第一附属医院郑州450003 2 河南中医药大学呼吸疾病中医药防治省部共建协同创新中心河南省中医药防治呼吸病重点实验室郑州450046 
摘要点击次数: 418
全文下载次数: 0
中文摘要:
      目的:采用网状Meta分析评价口服中成药治疗慢性阻塞性肺疾病(COPD)稳定期的有效性及安全性。方法:计算机检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD)、中国生物医学文献数据库(CBM)、PubMed、Embase、Web of Science、Cochrane library数据库中不同中成药治疗COPD稳定期的临床随机对照试验(RCT),检索时限为建库至2022年05月11日。采用R 4.1.1、Stata 16.0、Review manager 5.3软件进行数据分析。结果:共纳入70项RCT,包括6 652例患者,涉及5种中成药。依据累计概率值排序,网状Meta分析结果显示,改善COPD自我评估测试(CAT)问卷评分方面,百令胶囊+常规治疗(>常规治疗;改善第一秒用力呼气容积占预计值百分比(FEV1%)方面,百令胶囊+常规治疗>金水宝胶囊+常规治疗>补肺活血胶囊+常规治疗>玉屏风颗粒+常规治疗>常规治疗;改善六分钟步行距离(6MWD)方面,金水宝胶囊+常规治疗>补肺活血胶囊+常规治疗>百令胶囊+常规治疗>常规治疗;降低二氧化碳分压方面(PaCO2),补肺活血胶囊+常规治疗>金水宝胶囊+常规治疗>百令胶囊+常规治疗>常规治疗;降低年急性发作次数方面,百令胶囊+常规治疗>常规治疗。5种中成药均未产生严重不良反应。结论:5种中成药治疗稳定期COPD均能提高临床综合疗效,但各有侧重,其中百令胶囊组综合疗效较好。
English Summary:
      To evaluate the efficacy and safety of oral Chinese patent medicines for the treatment of stable chronic obstructive pulmonary disease(COPD) using network Meta-analysis.Methods:A computer-based search was conducted in the China National Knowledge Infrastructure(CNKI),China Academic Journals Database(CSPD),Chinese Science and Technology Journals Database(CCD),Chinese Biomedical Literature Database(CBM),PubMed,Embase,Web of Science,and Cochrane Library for clinical randomized controlled trials(RCTs) on different Chinese patent medicines for the treatment of stable COPD.The retrieval time was from the establishment of the databases until May 11,2022.Data analysis was performed using R4.1.1,Stata16.0,and Review Manager 5.3 software.Results:A total of 74 RCTs were included,involving 6652 patients and 5 types of Chinese patent medicines.Based on the ranking of cumulative probability values,the network Meta-analysis results were shown as follows.For improving COPD assessment test(CAT) questionnaire scores:Bailing capsules plus conventional treatment(CT) were superior to CT alone.For improving the percentage of forced expiratory volume in one second(FEV1%):Bailing Capsules plus CT were superior to Jinshuibao Capsules plus CT,which were superior to Bufei Huoxue Capsules plus CT,which were superior to Yupingfeng granules plus CT,which were superior to CT alone.For improving the six-minute walk distance(6MWD):Jinshuibao Capsules plus CT were superior to Bufei Huoxue Capsules plus CT,which were superior to Bailing Capsules plus CT,which were superior to CT alone.For reducing the partial pressure of carbon dioxide(PaCO2):Bufei Huoxue Capsules plus CT were superior to Jinshuibao Capsules plus CT,which were superior to Bailing Capsules plus CT,which were superior to CT alone.For reducing the annual number of acute exacerbations:Bailing Capsules plus CT were superior to CT alone.None of the five Chinese patent medicines caused serious adverse reactions.Conclusion:All five Chinese patent medicines can enhance the overall clinical efficacy in the treatment of stable COPD,each with its specific strengths.Among them,Bailing Capsules showed relatively better comprehensive efficacy.
查看全文  查看/发表评论  下载PDF阅读器